The global chronic venous occlusions treatment market size was valued at USD 8.32 billion in 2025 and is projected to grow from USD 8.84 billion in 2026 to USD 14.36 billion, registering a CAGR of6.25% during the forecast period (2026-2034). North America dominated the chronic venous occlusions treatment market with a share of 40.06% in 2025.
The chronic venous occlusions treatment market comprises medical treatments, procedures, and devices used to manage blockages or obstructions in veins that restrict normal blood flow. Treatment approaches include anticoagulant medications, and other invasive procedures used to restore venous circulation and reduce complications. These treatments are utilized across hospitals, specialty vascular centers, and interventional radiology departments to manage venous conditions and improve patient outcomes. Chronic venous occlusions treatment products are tracked under HSN Code 9018 (instruments and appliances used in medical, surgical, or diagnostic sciences) and SIC Code 8011 (offices and clinics of doctors of medicine).
The chronic venous occlusions treatment market demand is driven by the adoption of minimally invasive vascular procedures and a focus on improving blood circulation and preventing complications. Healthcare providers are adopting advanced treatment approaches, to restore blood flow and improve patient outcomes, contributing to the chronic venous occlusions treatment market growth.
Download a Free Sample To learn more about this report,
Evolution of Dedicated Venous Stent Technologies
The chronic venous occlusions treatment market analysis shows that medical device developers are advancing dedicated venous stent technologies designed specifically for venous anatomy and chronic obstruction treatment. This encourages manufacturers to develop flexible stent designs that accommodate vein movement, support vessel patency, and improve the treatment of complex venous lesions. Companies such as Boston Scientific have developed dedicated venous stent systems, including the VICI Venous Stent, for treating iliofemoral venous obstructions.
Integration of Intravascular Ultrasound in Venous Interventions
Influence of intravascular ultrasound (IVUS) is changing how clinicians assess venous obstructions and guide endovascular procedures. This transition is encouraging the use of real-time intravascular imaging to evaluate vessel dimensions, identify the extent of obstruction, and guide venous stent placement more accurately.
Supply chain disruptions are expected to have a moderate impact on the chronic venous occlusions treatment market share due to dependence on medical devices, vascular stents, and specialized medical components. The market is likely to follow an S-shaped recovery, with gradual restoration of medical device supplies and manufacturing operations. Supply chain constraints could reduce market growth by 1.0–1.5 percentage points, lowering the projected CAGR of 6.25% to around 4.75%–5.25%. As supply conditions normalize, the chronic venous occlusions treatment market growth is expected to stabilize.
The chronic venous occlusions treatment market forecasts strategic investment activity driven by the development of minimally invasive thrombectomy systems and advancements in venous stent technologies. In February 2026, SonoVascular completed the first close of a USD 6 million Series A financing led by Harbright Ventures to support regulatory and clinical milestones for its ultrasound-assisted SonoThrombectomy System, which removes blood clots associated with conditions such as deep vein thrombosis.
High Incidence of Post-Thrombotic Iliac Vein Obstruction and Treatment Needs for May-Thurner Syndrome Drive Market
Occurrence of chronic iliac vein obstruction following deep vein thrombosis is creating demand for treatments that restore venous blood flow and relieve persistent symptoms. Post-thrombotic scarring and narrowing lead to leg swelling, venous hypertension, pain, and post-thrombotic syndrome, particularly among patients with extensive iliofemoral thrombosis.
May-Thurner syndrome, a condition involving compression of the left common iliac vein, is creating a specific need for treatments that address chronic venous outflow obstruction. Angioplasty and venous stenting are supporting demand for chronic venous occlusion treatments by helping restore blood flow in suitable cases.
Uncertainty in Long-Term Stent Patency and Technical Challenges in Chronic Venous Recanalization Restrain Market Expansion
The long-term patency of iliocaval venous stents remains a clinical concern for patients with chronic post-thrombotic obstructions. Stent occlusion, restenosis, and recurrent venous blockage may require repeat interventions and continued imaging surveillance, creating uncertainty around long-term treatment outcomes.
Complex anatomy and extensive post-thrombotic scarring make the recanalization of long-segment iliocaval occlusions technically challenging for vascular specialists. The procedure requires advanced imaging, specialized devices, careful stent sizing, and adequate restoration of venous inflow and outflow to support patency.
Advancements in Intravascular Imaging and Development of Technologies to Improve Venous Stent Patency Offer Growth Opportunities
Advancements in intravascular ultrasound (IVUS) and venography are creating opportunities to improve the assessment of chronic venous occlusions and guide precise stent placement. These technologies help vascular specialists evaluate vessel dimensions, identify the extent of iliac vein obstruction, and select appropriate stent sizes and treatment strategies. Medical device manufacturers benefit from the demand for imaging-guided procedures that support accurate venous reconstruction and treatment planning.
The need to improve long-term venous stent patency is creating opportunities for manufacturers to develop dedicated stents with designs suited to complex iliocaval and post-thrombotic obstructions. Companies developing specialized venous stent systems benefit from demand for durable treatment options that maintain blood flow and reduce the need for repeat interventions.
Endovascular treatment led the treatment category with a share of 55.8% in 2025, owing to the preference for minimally invasive procedures, shorter recovery periods, and reduced hospital stays. Healthcare providers continue to use endovascular techniques for vascular disease management, supported by procedural advancements.
Surgical treatment is anticipated to record a growth rate of 5.42% during the forecast period, driven by the need for effective management of complex venous occlusions and cases requiring surgical intervention. Continued use of surgical procedures for patients who are unsuitable for endovascular treatment, along with the need for durable clinical outcomes, is expected to support segment growth.
Request Customizationto receive a tailored report.
Dedicated venous stents had a share of 34.9% in 2025, owing to their specialized design for treating venous obstructions and maintaining vessel patency. Healthcare providers continue to use dedicated venous stents for managing chronic venous occlusions, supporting their adoption across hospitals and specialized vascular treatment centers.
Imaging assistive devices segment are likely to grow at a CAGR of 6.89% during the forecast period, fueled by the demand for precise diagnosis and improved visualization of chronic venous occlusions.
In 2025, hospitals dominated the end-user category, accounting for a share of 62.4% in 2025. This dominance is led by the availability of advanced diagnostic equipment, specialized vascular care, and comprehensive treatment facilities.
Ambulatory surgical centers are anticipated to record a growth rate of 7.21% during the forecast period, driven by increasing preference for outpatient procedures, shorter recovery periods, and lower treatment costs. The use of minimally invasive interventions for chronic venous occlusions and the expansion of specialized outpatient facilities are expected to support segment growth.
Speak to an Analystto discuss market opportunities.
The North America chronic venous occlusions treatment market accounted for a dominant share of 40.06% in 2025.
U.S. Food and Drug Administration (FDA) regulates medical devices used in chronic venous occlusions treatment, including venous stents and catheter-based intervention systems, to ensure their safety and effectiveness. These regulatory requirements encourage manufacturers to develop advanced vascular devices, improve stent designs, and innovate minimally invasive technologies for treating chronic venous blockages and restoring blood flow.
According to the Canadian Institute for Health Information (CIHI), Canada’s healthcare system provides access to diagnostic imaging and specialized vascular care for patients with venous disorders, reflecting the need for effective diagnosis and treatment of circulatory conditions. Thus, the need to manage chronic venous blockages and restore blood flow supports demand for chronic venous occlusions treatment in Canada.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific chronic venous occlusions treatment market will expand at a CAGR of 8.12%, showcasing a rapidly growing regional market.
Japan’s Ministry of Health, Labour and Welfare supports the development and adoption of advanced medical technologies to improve treatment outcomes for patients with vascular disorders. These initiatives encourage the use of minimally invasive procedures, advanced venous stents, and catheter-based interventions for treating chronic venous blockages and restoring blood flow.
The Chinese market is supported by increasing diagnosis of venous disorders, expanding healthcare infrastructure, and the adoption of minimally invasive vascular procedures. Investments in advanced medical technologies and the expansion of specialized vascular care services continue to strengthen the country’s chronic venous occlusions treatment market.
India’s healthcare sector is witnessing increasing adoption of minimally invasive vascular procedures, including venous angioplasty, stenting, and catheter-based interventions for managing chronic venous blockages. These advancements support the development and use of improved treatment technologies, expanding access to vascular care and creating opportunities for medical device manufacturers and specialized healthcare providers across India.
Europe's chronic venous occlusions treatment market is anticipated to grow at a CAGR of 5.96% during the forecast period.
The UK vascular healthcare sector is focused on improving the diagnosis and treatment of chronic venous diseases through advances in minimally invasive procedures and specialized vascular services. Healthcare providers and medical device manufacturers are adopting improved venous stents, angioplasty techniques, and catheter-based interventions to restore blood flow, improve treatment outcomes, and address unmet needs in chronic venous occlusions care.
German Society for Vascular Surgery and Vascular Medicine (DGG) is preparing a registry to track interventions for chronic deep-vein occlusions, supporting the collection of clinical evidence and treatment outcomes. This initiative strengthens the clinical evidence base for endovascular procedures, including venous recanalisation and stent implantation, and supports demand for specialised catheters, guidewires and venous stents.
The Latin America chronic venous occlusions treatment market is expected to grow at a CAGR of 6.41% during the forecast period. Brazilian Society of Angiology and Vascular Surgery (SBACV) has laid down guidelines to address invasive treatment options for chronic venous disease and emphasise evidence-based decisions based on patient needs and available clinical resources. The Mexican Society of Angiology, Vascular and Endovascular Surgery (SMACVE) endorsed clinical guidance on upper-extremity deep vein thrombosis, addressing diagnostic and treatment approaches, including endovascular interventions.
The Middle East & Africa chronic venous occlusions treatment market is expected to grow at a CAGR of 6.68% during the forecast period. In the UAE, hospitals such as Dubai Medical University Hospital offer vascular services that include catheter-based interventions and stent placement, supporting access to advanced treatments for venous disorders. In South Africa, the development of endovascular treatment capabilities and the use of angioplasty and stenting technologies support the management of vascular blockages and related complications.
The chronic venous occlusions treatment market competitive landscape is competitive, with established medical device manufacturers, vascular intervention specialists, and healthcare technology providers. Key players such as Boston Scientific Corporation, Medtronic plc, BD, Cook Medical, and Philips are estimated to account for 30–40% of the global chronic venous occlusions treatment market share.
Established players compete mainly through venous stenting technologies, minimally invasive treatment devices, catheter-based interventions. Regional players in the chronic venous occlusions treatment market ecosystem focus on cost-effective treatment solutions, specialized vascular devices, and expanded access to venous disease management services.
July 2026: enVVeno Medical reported that the TAVVE pivotal study was expected to begin enrolling patients in the second half of 2026, with plans to evaluate the enVVe System at up to 40 U.S. clinical sites.
April 2026: enVVeno Medical received U.S. FDA approval for an Investigational Device Exemption (IDE) to begin its pivotal TAVVE clinical study of the enVVe System, a minimally invasive replacement venous valve for patients with severe deep chronic venous insufficiency.
February 2026: Philips received U.S. FDA approval for updated instructions for use for its Duo Venous Stent System, incorporating final results from the VIVID clinical study.
December 2025: W. L. Gore & Associates received U.S. FDA approval for its GORE VIABAHN FORTEGRA Venous Stent to treat symptomatic inferior vena cava obstruction, with or without combined iliofemoral obstruction.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Autosomal Dominant Polycystic Kidney Disease Market Size, Forecast, 2034
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
Chemotherapy Induced Thrombocytopenia Market Size, Forecast, Opportunities, 2034
Cardiometabolic Disease Market Size, Share, Growth, Analysis, 2034
Clot Busting Drugs Market Size, Forecast, Demand, Opportunities, 2034
Antibody Drug Conjugates Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com